Abstract:N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a critical negative regulator of fibrosis development in the liver. However, its extremely short half-life in vivo greatly compromises its potential applications. Here, we report an Ac-SDKP analog peptide with d-amino acid replacement (Ac-SDDKDP). The stability of Ac-SDDKDP and its prevention of liver fibrosis were investigated in vitro and in vivo. The stabilities of Ac-SDKP and Ac-SDDKDP exposed to angiotensin-1-converting enzyme (ACE) and their half-lives in rats and human sera were determined by high-performance liquid chromatography. The inhibitory effects of Ac-SDKP and Ac-SDDKDP on the proliferation and activation of hepatic stellate cells (HSC-T6) were evaluated using the Cell Counting Kit-8, Western blotting, reverse transcription quantitative polymerase chain reaction, and immunofluorescence assays. Finally, the protective effects of Ac-SDKP and Ac-SDDKDP on carbon tetrachloride (CCl4)-induced liver fibrosis in rats were compared. d-Amino acid replacement significantly enhanced the stability of the peptide to ACE and prolonged the half-life of Ac-SDKP in rats and human sera. The Ac-SDKP-mediated inhibition of HSC-T6 cell proliferation was well preserved, and Ac-SDDKDP exerted inhibitory effects comparable to Ac-SDKP on alpha-smooth muscle actin (alpha-SMA), collagen I and III expression, and phosphorylated-Smad-2 expression. After intraperitoneal (i.p.) administration, Ac-SDDKDP exhibited significantly greater protection than Ac-SDKP against CCl4-induced liver fibrosis in rats. The serum alanine aminotransferase, aspartate aminotransferase, albumin, and total protein levels of the Ac-SDDKDP-treated rats were significantly lower than those of the Ac-SDKP-treated rats. alpha-SMA, CD45, and collagen I and III expression, as well as Smad-2 phosphorylation were significantly attenuated in the livers of the Ac-SDDKDP-treated rats compared to those of the Ac-SDKP-treated rats. Furthermore, we showed that the Ac-SDDKDP concentration in the rat liver increased to a physiological level of 60 min after i.p. administration, although i.p. administration of Ac-SDKP failed to enhance the peptide concentration in the rat liver. Our findings indicate that d-amino acid replacement is a simple and effective method to enhance the stability of Ac-SDKP. Ac-SDDKDP represents potential application of Ac-SDKP in fibrosis treatment and provides a new potential treatment strategy for liver fibrosis. (c) 2019 IUBMB Life, 71(9):1302-1312, 2019

D-Amino Acid Modification Protects N-Acetyl-seryl-aspartyl-lysyl-proline from Physiological Hydroxylation and Increases Its Antifibrotic Effects on Hepatic Fibrosis

Preservation of Basal AcSDKP Attenuates Carbon Tetrachloride-Induced Fibrosis in the Rat Liver

Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitigates the liver fibrosis via WTAP/m6A/Ptch1 axis through Hedgehog pathway

Fluorofenidone Attenuates Hepatic Fibrosis By Suppressing The Proliferation And Activation Of Hepatic Stellate Cells

Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury.

The Antihepatic Fibrotic Effects of Fluorofenidone Via Mapk Signalling Pathways

Antiproliferative Effects of the Hemoregulatory Inhibitor N-acetyl-seryl-aspartyl-lysyl-proline on Rat Renal Interstitial Fibroblasts

Effects of AcSDKP on Synthesis and Secretion of Extracellular Matrix in Hepatic Stellate Cells Mediated by TGF-β1

Diisopropylamine Dichloroacetate Alleviates Liver Fibrosis Through Inhibiting Activation And Proliferation Of Hepatic Stellate Cells

N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice

Phospholipid Encapsulation of an Anti-Fibrotic Endopeptide to Enhance Cellular Uptake and Myocardial Retention

Saikosaponin-d protects against liver fibrosis by regulating the estrogen receptor-β/NLRP3 inflammasome pathway

Asiatic Acid Inhibits Liver Fibrosis By Blocking Tgf-Beta/Smad Signaling In Vivo And In Vitro

Study on the Antifibrotic Effects of Recombinant Shark Hepatical Stimulator Analogue (r-sHSA) in Vitro and in Vivo

Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Effects of AcSDKP on Proliferation and Secretion of Extracellular Matrix in Rat Active Hepatic Stellate Cells

Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells